Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Exclusion Criteria

• •1. Subjects have received or plan to receive endovascular treatment and/or intravenous thrombolytic therapy recommended by Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2018 during this onset period;
• •2. Presence of disturbances of consciousness at screening and NIHSS 1a ≥ 2 points;
• •3. Neurological signs have improved rapidly and spontaneously at screening;
• •4. Subjects who have used or are using protocol-prohibited medications after the onset;
• •5. Subjects with pre-stroke disability;
• •6. Subjects with intracranial hemorrhagic diseases, tumor in brain parenchyma, arteriovenous malformation, aortic arch dissection, other central nervous system lesions that may increase the risk of hemorrhage, or imaging evidence for arterial aneurysm requiring treatment;
• •7. Massive infarction on imaging;
• •8. Patients who are unable to cooperate due to epileptic seizure at the onset of stroke or other concomitant mental disorders or are unwilling to cooperate;
• •9. Systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg after active antihypertensive therapy;
• •10. Acute hemorrhage tendency;
• •11. Blood glucose level \< 50 mg/dL or \> 400 mg/dL;
• •12. Active visceral hemorrhage;
• •13. Lactating or pregnant subjects, or women of childbearing potential with positive pregnancy test results;
• •14. International normalized ratio \> 1.7 or prothrombin time \> 15 s;
• •15. Subjects with a history of serious hypersensitivity;
• •16. Subjects who experienced AIS, ICH, acute myocardial infarction or serious head trauma before screening;
• •17. Subjects who underwent any major surgery before screening;
• •18. Subjects with a history of active digestive ulcer before screening;
• •19. Subjects who experienced hemorrhagic disease before screening;
• •20. Subjects who underwent arterial puncture at the site not easy for hemostasis by compression before screening;
• •21. Serious hepatic impairment or serious renal insufficiency;
• •22. Subjects who have participated in another investigational study and used investigational product before screening;
• •23. Other conditions unsuitable for participation in this study determined by the Investigator.